Therapeutic uses of recombinant complement protein inhibitors
Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1994 |
|---|
| Umfang: |
15 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Springer seminars in immunopathology - 1978, 15(1994) vom: Apr., Seite 417-431 |
| Übergeordnetes Werk: |
volume:15 ; year:1994 ; month:04 ; pages:417-431 ; extent:15 |
| Links: |
|---|
| Katalog-ID: |
NLEJ20302981X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ20302981X | ||
| 003 | DE-627 | ||
| 005 | 20230505203056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1994 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ20302981X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Therapeutic uses of recombinant complement protein inhibitors |
| 264 | 1 | |c 1994 | |
| 300 | |a 15 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Kalli, Kimberly R. |4 oth | |
| 700 | 1 | |a Hsu, Peihong |4 oth | |
| 700 | 1 | |a Fearon, Douglas T. |4 oth | |
| 773 | 0 | 8 | |i in |t Springer seminars in immunopathology |d 1978 |g 15(1994) vom: Apr., Seite 417-431 |w (DE-627)NLEJ188991247 |w (DE-600)1481154-6 |x 1432-2196 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:1994 |g month:04 |g pages:417-431 |g extent:15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01837368 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 1994 |c 4 |h 417-431 |g 15 | ||
| matchkey_str |
article:14322196:1994----::hrpuiueorcmiatopeet |
|---|---|
| hierarchy_sort_str |
1994 |
| publishDate |
1994 |
| allfields |
(DE-627)NLEJ20302981X DE-627 ger DE-627 rakwb eng Therapeutic uses of recombinant complement protein inhibitors 1994 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts. Springer Online Journal Archives 1860-2002 Kalli, Kimberly R. oth Hsu, Peihong oth Fearon, Douglas T. oth in Springer seminars in immunopathology 1978 15(1994) vom: Apr., Seite 417-431 (DE-627)NLEJ188991247 (DE-600)1481154-6 1432-2196 nnns volume:15 year:1994 month:04 pages:417-431 extent:15 http://dx.doi.org/10.1007/BF01837368 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 15 1994 4 417-431 15 |
| spelling |
(DE-627)NLEJ20302981X DE-627 ger DE-627 rakwb eng Therapeutic uses of recombinant complement protein inhibitors 1994 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts. Springer Online Journal Archives 1860-2002 Kalli, Kimberly R. oth Hsu, Peihong oth Fearon, Douglas T. oth in Springer seminars in immunopathology 1978 15(1994) vom: Apr., Seite 417-431 (DE-627)NLEJ188991247 (DE-600)1481154-6 1432-2196 nnns volume:15 year:1994 month:04 pages:417-431 extent:15 http://dx.doi.org/10.1007/BF01837368 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 15 1994 4 417-431 15 |
| allfields_unstemmed |
(DE-627)NLEJ20302981X DE-627 ger DE-627 rakwb eng Therapeutic uses of recombinant complement protein inhibitors 1994 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts. Springer Online Journal Archives 1860-2002 Kalli, Kimberly R. oth Hsu, Peihong oth Fearon, Douglas T. oth in Springer seminars in immunopathology 1978 15(1994) vom: Apr., Seite 417-431 (DE-627)NLEJ188991247 (DE-600)1481154-6 1432-2196 nnns volume:15 year:1994 month:04 pages:417-431 extent:15 http://dx.doi.org/10.1007/BF01837368 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 15 1994 4 417-431 15 |
| allfieldsGer |
(DE-627)NLEJ20302981X DE-627 ger DE-627 rakwb eng Therapeutic uses of recombinant complement protein inhibitors 1994 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts. Springer Online Journal Archives 1860-2002 Kalli, Kimberly R. oth Hsu, Peihong oth Fearon, Douglas T. oth in Springer seminars in immunopathology 1978 15(1994) vom: Apr., Seite 417-431 (DE-627)NLEJ188991247 (DE-600)1481154-6 1432-2196 nnns volume:15 year:1994 month:04 pages:417-431 extent:15 http://dx.doi.org/10.1007/BF01837368 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 15 1994 4 417-431 15 |
| allfieldsSound |
(DE-627)NLEJ20302981X DE-627 ger DE-627 rakwb eng Therapeutic uses of recombinant complement protein inhibitors 1994 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts. Springer Online Journal Archives 1860-2002 Kalli, Kimberly R. oth Hsu, Peihong oth Fearon, Douglas T. oth in Springer seminars in immunopathology 1978 15(1994) vom: Apr., Seite 417-431 (DE-627)NLEJ188991247 (DE-600)1481154-6 1432-2196 nnns volume:15 year:1994 month:04 pages:417-431 extent:15 http://dx.doi.org/10.1007/BF01837368 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 15 1994 4 417-431 15 |
| language |
English |
| source |
in Springer seminars in immunopathology 15(1994) vom: Apr., Seite 417-431 volume:15 year:1994 month:04 pages:417-431 extent:15 |
| sourceStr |
in Springer seminars in immunopathology 15(1994) vom: Apr., Seite 417-431 volume:15 year:1994 month:04 pages:417-431 extent:15 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Springer seminars in immunopathology |
| authorswithroles_txt_mv |
Kalli, Kimberly R. @@oth@@ Hsu, Peihong @@oth@@ Fearon, Douglas T. @@oth@@ |
| publishDateDaySort_date |
1994-04-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188991247 |
| id |
NLEJ20302981X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ20302981X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505203056.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ20302981X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutic uses of recombinant complement protein inhibitors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kalli, Kimberly R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hsu, Peihong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fearon, Douglas T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Springer seminars in immunopathology</subfield><subfield code="d">1978</subfield><subfield code="g">15(1994) vom: Apr., Seite 417-431</subfield><subfield code="w">(DE-627)NLEJ188991247</subfield><subfield code="w">(DE-600)1481154-6</subfield><subfield code="x">1432-2196</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:1994</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:417-431</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01837368</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">1994</subfield><subfield code="c">4</subfield><subfield code="h">417-431</subfield><subfield code="g">15</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188991247 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-2196 |
| topic_title |
Therapeutic uses of recombinant complement protein inhibitors |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k r k kr krk p h ph d t f dt dtf |
| hierarchy_parent_title |
Springer seminars in immunopathology |
| hierarchy_parent_id |
NLEJ188991247 |
| hierarchy_top_title |
Springer seminars in immunopathology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188991247 (DE-600)1481154-6 |
| title |
Therapeutic uses of recombinant complement protein inhibitors |
| spellingShingle |
Therapeutic uses of recombinant complement protein inhibitors |
| ctrlnum |
(DE-627)NLEJ20302981X |
| title_full |
Therapeutic uses of recombinant complement protein inhibitors |
| journal |
Springer seminars in immunopathology |
| journalStr |
Springer seminars in immunopathology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1994 |
| contenttype_str_mv |
zzz |
| container_start_page |
417 |
| container_volume |
15 |
| physical |
15 |
| format_se |
Elektronische Aufsätze |
| title_sort |
therapeutic uses of recombinant complement protein inhibitors |
| title_auth |
Therapeutic uses of recombinant complement protein inhibitors |
| abstract |
Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts. |
| abstractGer |
Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts. |
| abstract_unstemmed |
Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Therapeutic uses of recombinant complement protein inhibitors |
| url |
http://dx.doi.org/10.1007/BF01837368 |
| remote_bool |
true |
| author2 |
Kalli, Kimberly R. Hsu, Peihong Fearon, Douglas T. |
| author2Str |
Kalli, Kimberly R. Hsu, Peihong Fearon, Douglas T. |
| ppnlink |
NLEJ188991247 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| up_date |
2024-07-06T09:37:11.936Z |
| _version_ |
1803821915240923136 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ20302981X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505203056.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ20302981X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutic uses of recombinant complement protein inhibitors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Conclusion In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kalli, Kimberly R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hsu, Peihong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fearon, Douglas T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Springer seminars in immunopathology</subfield><subfield code="d">1978</subfield><subfield code="g">15(1994) vom: Apr., Seite 417-431</subfield><subfield code="w">(DE-627)NLEJ188991247</subfield><subfield code="w">(DE-600)1481154-6</subfield><subfield code="x">1432-2196</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:1994</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:417-431</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01837368</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">1994</subfield><subfield code="c">4</subfield><subfield code="h">417-431</subfield><subfield code="g">15</subfield></datafield></record></collection>
|
| score |
7.4007807 |